| Literature DB >> 32293381 |
Toni Kiljander1, Tuija Poussa2, Timo Helin3, Antero Jaakkola4, Kari Venho5, Lauri Lehtimäki6,7.
Abstract
BACKGROUND: Surprisingly little is known about asthma control among asthmatics who smoke. The aim of this cross-sectional study was to investigate asthma symptom control according to the GINA guidelines among asthmatics with a clinically significant smoking history.Entities:
Keywords: Asthma; Smoking; Symptom control
Mesh:
Substances:
Year: 2020 PMID: 32293381 PMCID: PMC7158041 DOI: 10.1186/s12890-020-1127-9
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Patient characteristics for the whole group of asthmatics who had a smoking history of at least 10 pack-years, and according to asthma symptom control level as per the GINA guidelines
| All subjects | Well controlled | Partially controlled | Uncontrolled | ||
|---|---|---|---|---|---|
| Age (years) | 58.0 (50.0–65.0) | 59.5 (52.0–65.0) | 57.0 (49.0–65.0) | 58.0 (49.0–64.0) | 0.79 |
| Females | 112 (58.9) | 36 (54.5) | 46 (56.8) | 30 (69.8) | 0.25 |
| BMI (kg/m2) | 27.5 (24.2–31.1) | 26.3 (24.2–30.1) | 27.5 (24.3–31.2) | 27.9 (23.9–33.3) | 0.47 |
| Current smokers | 83 (44.1) | 23 (35.4) | 34 (42.0) | 26 (61.9) | 0.02 (0.01)*** |
| Pack-years | 20.0 (15.0–30.0) | 20.0 (15.0–30.0) | 20.0 (15.0–27.0) | 26.0 (15.0–35.0) | 0.25 |
| FEV1 (% of predicted) | 80.5 (71.0–93.0) | 84.0 (71.0–94.0) | 83.0 (72.0–95.0) | 78.0 (67.0–83.0) | 0.03 (0.03)** |
| Significant reversibility in FEV1 | 17 (8.9) | 5 (7.6) | 5 (6.2) | 7 (16.3) | 0.15 |
| Post-bronchodilator FEV1/FVC | 0.74 (0.68–0.79) | 0.73 (0.68–0.77) | 0.75 (0.70–0.81) | 0.72 (0.68–0.80) | 0.24 |
| Post bronchodilator FEV1/FVC < 0.70 | 52 (27.4) | 17 (25.8) | 22 (27.2) | 13 (30.2) | 0.88 |
| Exacerbation during previous year | 51 (26.8) | 7 (10.6) | 27 (33.3) | 17 (39.5) | 0.001 (< 0.001)*** |
| Regular use of inhaled corticosteroid | 179 (94.2) | 63 (95.5) | 77 (95.1) | 39 (90.7) | 0.53 |
Regular use of inhaled corticosteroid + long-acting b2-agonist (ICS + LABA) | 122 (64.2) | 42 (63.6) | 56 (69.1) | 24 (55.8) | 0.34 |
The results are given as the median (interquartile range) or number of patients (percentage)
*Kruskal-Wallis test was used for continuous variables, and the chi-squared test was used for comparisons of categorical variables among groups according to asthma control
**Jonckheere-Terpstra trend test in parentheses
***Mantel-Haenzel trend test in parentheses
Asthma symptom control according to patient characteristics. Univariate logistic regression analysis was used to analyse the associations with the asthma control levels ‘Well controlled’ and ‘Uncontrolled’
| Asthma symptom control | Univariate logistic regression analyses | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Well controlled | Partly controlled | Uncontrolled | Dependent variable is | Dependent variable is | ||||||
| OR | 95% CI | P | OR | 95% CI | P | |||||
| Smoking | Ex-smoker ( | 42 (40.0) | 47 (44.8) | 16 (15.2) | ||||||
| Current smoker ( | 23 (27.7) | 34 (41.0) | 26 (31.3) | 0.58 | 0.31–1.07 | 0.08 | 2.54 | 1.25–5.14 | 0.01 | |
| Pack-years | < 30 ( | 47 (35.3) | 61 (45.9) | 25 (18.8) | ||||||
| ≥30 ( | 19 (33.3) | 20 (35.1) | 18 (31.6) | 0.91 | 0.47–1.76 | 0.79 | 1.99 | 0.98–4.05 | 0.06 | |
| Sex | Female ( | 36 (32.1) | 46 (41.1) | 30 (26.8) | ||||||
| Male ( | 30 (38.5) | 35 (44.9) | 13 (16.7) | 1.32 | 0.72–2.41 | 0.37 | 0.55 | 0.26–1.13 | 0.10 | |
| Exacerbationa | No ( | 59 (42.4) | 54 (38.8) | 26 (18.7) | ||||||
| Yes ( | 7 (13.7) | 27 (52.9) | 17 (33.3) | 0.22 | 0.09–0.51 | 0.001 | 2.17 | 1.06–4.47 | 0.04 | |
| ICS | No ( | 3 (27.3) | 4 (36.4) | 4 (36.4) | ||||||
| Yes ( | 63 (35.2) | 77 (43.0) | 39 (21.8) | 1.45 | 0.37–5.65 | 0.59 | 0.49 | 0.14–1.75 | 0.49 | |
| ICS + LABA | No ( | 24 (35.3) | 25 (36.8) | 19 (27.9) | ||||||
| Yes ( | 42 (34.4) | 56 (45.9) | 24 (19.7) | 0.96 | 0.52–1.79 | 0.90 | 0.63 | 0.32–1.26 | 0.19 | |
| FEV1/FVC < 0.70b | No( | 49 (35.5) | 59 (42.8) | 30 (21.7) | ||||||
| Yes ( | 17 (32.7) | 22 (42.3) | 13 (25.0) | 0.88 | 0.45–1.73 | 0.72 | 1.20 | 0.57–2.53 | 0.63 | |
| FEV1, % of predicted | ≥ 80% | 40 (39.6) | 44 (43.6) | 17 (16.8) | ||||||
| < 80% | 26 (29.2) | 37 (41.6) | 26 (29.2) | 0.63 | 0.34–1.15 | 0.13 | 2.04 | 1.02–4.08 | 0.04 | |
| Significant reversibilityc | No ( | 61 (35.3) | 76 (43.9) | 36 (20.8) | ||||||
| Yes ( | 5 (29.4) | 5 (29.4) | 7 (41.2) | 0.77 | 0.26–2.27 | 0.63 | 2.66 | 0.95–7.49 | 0.06 | |
ahospitalization and/or oral corticosteroids for asthma during the previous year, bpost-bronchodilator, cchange in FEV1 at least 12% and 200 ml